Correction: Optimized Ginkgo biloba extract EGb 761®: boosted therapeutic benefits with minimized CYP enzyme interference

Abstract

A correction refers to a change to their article that the author wishes to publish after publication. The publication of this article is subject to Frontiers' editorial approval.Instructions:• Please read through all the templates before choosing • Pick the most relevant text template(s) from the following page and delete all others.• Edit the text as necessary, ensuring that the original incorrect text is included for the record, please see the below. • Please do not use any extra formatting when editing the templates, and only modify the red text unless absolutely necessary • Submit to Frontiers following the instructions on this page.When the original text contained incorrect information, to preserve the scientific record, please include that text when editing the below templates. For example:There was a mistake in the Funding statement, an incorrect number was used.The correct number is "2015C03Bd051.". The publisher apologizes for this mistake.The original version of this article has been updated. In the published article, references [27,28] were cited in the Conclusion section. Due to the text correction listed below, these citations should be removed. The original version of this article has been updated. Adding/removing text In the published article, there is an erroneous statement in the Conclusion section: "The potential inhibitory effects of PCA on CYP1A2, CYP2E1, CYP2D6, and CYP3A4 have been reported based on molecular docking simulations [27]. In particular, in vivo animal studies have demonstrated that PCA inhibits the enzymatic activity of CYP1A2 and CYP2E1 [28]. On the basis of prior research, it is reasonable to hypothesize that the enhanced CYP inhibition observed in EGb 761®, A4, and B2 is associated with their high concentrations of PCA." A correction has been made to the section [Conclusion]: "While a direct causal relationship between reduced CYP inhibitory activity and PCA could not be definitively confirmed-due to the presence of numerous other compounds in EGb 761® and other raw materials or final drug products-further research is needed to clarify this relationship, as the chemical composition of G. biloba extracts is welldocumented." The original version of this article has been updated.